NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on May 8, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time.
Conference Call & Webcast Details
| Date: | Wednesday, May 8th |
| Time: | 4:30 p.m. Eastern time |
| Toll-Free Dial-In: | 1-888-886-7786 |
| International Dial-In: | 1-416-764-8658 |
| Conference ID: | 51137398 |
| Live & Archived Webcast: | Link |
About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Investor Contact
Marc Benathen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Jessica Friedeman, Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.10 |
| Daily Change: | -0.12 -2.30 |
| Daily Volume: | 210,355 |
| Market Cap: | US$220.880M |
November 07, 2024 November 06, 2024 October 23, 2024 September 19, 2024 August 07, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
